Fund manager Tarek Sherif moved into a small office with young tech entrepreneur and researcher, Glen de Vries, who hand-coded ƵAPP’s original software. The two worked with Ed Ikeguchi and founded ƵAPP in 1999.
Our Story
More than 20 years ago, ƵAPP was founded with the hope of powering smarter treatments and healthier people. Today, ƵAPP leads the digital transformation of life sciences, creating hope for millions of patients. We help generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. ƵAPP, a Dassault Systèmes company, is headquartered in New York City and has offices around the world to meet the needs of its customers.
Timeline
ƵAPP is Founded
Launch of Electronic Data Capture (EDC)
The collection of data in clinical trials was forever changed by the launch of Rave, the first software to digitally collect clinical trial data. Later named Rave EDC (Electronic Data Capture), it quickly becomes the most advanced, robust, and secure EDC system for clinical trial site, patient, and lab data capture and management in the world.
ƵAPP Opens London Office
ƵAPP Opens Tokyo Office
Launch of ƵAPP NEXT
From customer requests for a Rave users forum to share best practices in the use of the solution, the ƵAPP User Group (MUG) was born. As the annual event grew in both attendance and scope, MUG was rebranded as ƵAPP Symposium in 2015 and as ƵAPP NEXT in 2017. ƵAPP NEXT brings together key industry leaders, change-makers, and patient advocates to shape the future of life sciences.
Initial Public Offering on NASDAQ
Acquisition of Clinical Force
The acquisition of Clinical Force adds ƵAPP CTMS® (clinical trial management system) to solutions.
Acquisition of Mytrus
The acquisition of Mytrus adds eConsent to the ƵAPP Rave® Platform.
Acquisition of CHITA
The acquisition of CHITA adds regulated content management and eTMF capabilities to the ƵAPP Rave® Platform.
Acquisition of SHYFT Analytics
The acquisition of SHYFT Analytics, powers ƵAPP customers’ digital transformation with AI and real-world analytics.
Launch of ƵAPP AI
ƵAPP AI launched in 2019, combining data, technology, and deep expertise to help life sciences companies deliver actionable insights across the entire continuum of clinical development. ƵAPP AI’s advanced analytics answers the most important questions in R&D and commercialization including accelerating breakthrough innovation, optimizing study execution and commercial success, and demonstrating the value of therapies.
Dassault Systèmes Acquires ƵAPP
Dassault Systèmes, the 3DEXPERIENCE Company, acquired ƵAPP to drive the digital transformation of life sciences in the age of personalized medicine and patient-centric experience. Through this combination, the companies will push the boundaries of innovation, learning and production to achieve a more sustainable world for patients, citizens, and consumers.
ƵAPP Helps Life Science Companies Navigate COVID-19
Over the course of 2020, ƵAPP published nine White Papers detailing the implications of COVID-19 on existing and new drug and vaccine studies. COVID-19 and Clinical Trials: The ƵAPP Perspective also reviewed the impact on patients, and shared a range of solutions to support the continuation of current clinical studies around the world.
Launch of myƵAPP
Built for patients, by patients, myƵAPP is an award-winning single destination patient portal, allowing patients to use any online device to virtually learn, enroll and engage in clinical trials. Only myƵAPP enables the full range of tools to build scalable, flexible solutions at every level of decentralized and hybrid clinical trials.
ƵAPP Supports Moderna’s COVID-19 Vaccine Trials
ƵAPP’s suite of technologies supported the advancement of Moderna’s mRNA-1273 clinical trials, including the Phase 3 trial, which enrolled more than 30,000 participants. The ƵAPP and Moderna teams moved forward with the speed and urgency necessitated by the global pandemic, using ƵAPP’s innovative and scalable cloud platform for clinical development.
ƵAPP Synthetic Control Arm® Supported by the FDA
In a regulatory first, the US Food and Drug Administration (FDA) allowed Medicenna Therapeutics, Corp. to use a hybrid external control arm in a phase 3 registrational trial. The phase 2 single arm trial preceding this phase 3 study in recurrent glioblastoma, an aggressive form of brain cancer, was also enhanced by a synthetic control arm.
Launch of myƵAPP Registries
ƵAPP Launches myƵAPP Registries, a new technology that expands and strengthens the myƵAPP patient portal to engage patients before and after (i.e., long term follow up/safety surveillance) a clinical trial.
The First to Offer End-to-End, Unified Platform for DCTs
ƵAPP launched the most comprehensive set of unified, secure technologies that enable decentralized clinical trials (DCTs) across the development continuum. For the first time ever, drug, vaccine, and medical device developers (sponsors) and contract research organizations (CROs) can take advantage of the only platform offering on the market.
ƵAPP Launches Sensor Cloud
ƵAPP Sensor Cloud provides cutting-edge common data models and proprietary algorithms enabling rapid ingestion, normalization and analysis of patient data resulting in better clinical decision making, faster timelines and a more patient-centric experience.
The Sensor Cloud Network, creating the first industry-wide collaboration amongst contract research organizations (CROs), device manufacturers, drug and vaccine developers, analytics companies, and academia, was launched in October 2021.
Rave Imaging 1000th Trial
ƵAPP Rave Imaging, the company’s cloud-based, secure clinical trial imaging management platform, reached a significant milestone, having supported more than 1,000 imaging studies. Rave Imaging, built on the ƵAPP Unified Platform, processes more than 100 million images annually.
ƵAPP Mourns the Loss of Co-Founder Glen de Vries
Glen de Vries, co-founder of ƵAPP, died in a plane crash, weeks after fulfilling his lifelong dream of traveling to space. Glen had an incredible impact on the life science industry and left a lasting legacy of improving the clinical development process, bringing new drugs, vaccines, and diagnostics – and hope – to patients around the world.
ƵAPP Opens Access to its Patient Insights Program
ƵAPP announced it is allowing sponsors, CROs (contract research organizations), and sites to leverage its proprietary Patient Insights Program. The program infuses the patient perspective into the software development life cycle to create technical solutions that improve the overall patient experience in clinical research operations.
30,000 Trials & 9 Million Participants Milestone
ƵAPP Becomes First Life Sciences Technology Company to Exceed 30,000 Clinical Trials and 9 Million Study Volunteers.
You decide what cookies ƵAPP will use
Your preferences will be kept for 6 months and you can change them at any time by clicking on the "Manage my cookies preferences" link in the footer of each webpage. To learn more about how this site uses cookies, please visit our privacy policy.
What are cookies?
Complete details can be found in our Privacy Policy.
Necessary cookies are essential and are used to provide you with services available through ƵAPP website. For instance, these cookies allow ƵAPP to remember your choices about cookies preferences, to record your interface customization trackers e.g. for the choice of language used by the website. Necessary cookies are enabled by default and cannot be switched off. To see the list of the cookies used for this purpose, click here .
Functional cookies are used to provide you with contents and proposals that correspond to your interactions. They may consist of information logged on your device or recorded as you navigate through ƵAPP website. These cookies also allow us to analyze site usage so we can measure and improve performance. To see the list of the cookies used for these purposes, click here.
Advertising cookies are used to enable ƵAPP and its trusted ƵAPP business stakeholders to serve ads that are relevant to your interests. The intention is to display ads that are relevant to you.
- Microsoft Clarity
- Microsoft Bing
- Mouseflow
- Oracle / Eloqua
- 6sense
- Autodesk
To see the list of the cookies used for this purpose, click here.